SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending after a recent proposal from the Centers for Medicare & Medicaid Services indicated a near-flat increase in Medicare Advantage rates for 2027, significantly below market expectations. This news has sparked a sector-wide sell-off and intense community discussion, with some investors expressing panic over potential margin pressure, while others view it as an overreaction and a buying opportunity ahead of anticipated pre-market earnings. The debate centers on whether the proposed rates represent a lasting policy shift or a temporary market shakeout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing a surge in attention following famed investor Michael Burry's disclosure of a long-term position, building on recent insider buying from CEO Ryan Cohen. The community is actively debating whether this signals a fundamental turnaround or a catalyst for renewed speculative interest and a potential short squeeze, with many eagerly awaiting further developments.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is experiencing extreme volatility and trending due to intense community debate surrounding a potential silver short squeeze. Discussions highlight unprecedented price surges driven by strong industrial and central bank demand, alongside skepticism from bears predicting a 'blow off top' and significant correction.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is seeing significant trading activity as silver experiences a parabolic rise, fueled by speculation around China's new silver export restrictions and growing industrial demand for clean energy applications. The community is fiercely divided between exuberant bulls expecting further gains due to perceived supply shortages and bears warning of an overextended bubble ripe for a sharp correction.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is trending due to significant ongoing stock depreciation, fueled by a recent CFO transition and an adjusted earnings release date that has intensified community frustration. Investors are actively debating leadership's perceived inaction, lack of insider buying, and competitive pressures from 'walled garden' advertising platforms, with many questioning the stock's future while others view it as deeply undervalued ahead of a pivotal earnings report.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to its recent $1.8 billion acquisition of SkyWater Technology, a strategic move aiming to vertically integrate its quantum chip production and accelerate its technology roadmap. While some investors see this as a pivotal step towards becoming a quantum industry leader with national security implications, others are concerned about potential shareholder dilution and the valuation of the deal, sparking active debate and market volatility.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is a significant focus for market participants as its earnings approach, with multiple analysts issuing upgraded price targets citing strong AI integration, cost control efforts, and new monetization initiatives such as subscriptions and Threads. The community is actively debating whether the substantial investments in AI will translate into a significant earnings beat and valuation re-rating, or if ongoing regulatory scrutiny and high capital expenditures will lead to a market reassessment. This discussion underscores the broader investor sentiment around mega-cap technology companies' AI profitability and future growth trajectories.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending as the Centers for Medicare & Medicaid Services (CMS) proposed an average 0.09% increase in 2027 Medicare Advantage rates, vastly undercutting market expectations. This news has triggered widespread investor concern about significant margin pressure across the managed care sector, prompting community discussions on whether the sharp stock drop presents a buying opportunity or signals ongoing policy headwinds for Humana and its peers.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending with silver's explosive move into triple-digit territory, fueled by recent company announcements of record production and a significant dividend increase. The community is actively discussing the perceived undervaluation of silver miners relative to the metal's price and anticipating a substantial catch-up, with many expecting further gains amidst tightening physical supply and upcoming earnings reports.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors eagerly await its upcoming earnings report, which follows a period of notable delivery improvements and increased orders, including new widebody commitments from a major airline. While many are optimistic about potential positive guidance and a sustained turnaround, a significant portion of the community expresses caution regarding profit-taking or lingering production challenges. The broader aerospace sector is closely watching for confirmation of a durable recovery amid shifting market dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.

<ul class="summary-bullets"><li>The U.S. Food and Drug Administration did not request any additional clinical studies or new patient data, as per the company.</li><li>Capricor now plans to submit the data requested by the FDA in February.</li><li>CEO Linda Marbán said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 2% on Tuesday morning after the company said that the U.S. Food and Drug Administration (FDA) has requested more data from its trials of Deramiocel.In July, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/capricor-therapeutics-stock-sparks-retail-frenzy-as-traders-hail-best-data-ahead-of-dmd-data-rollout/cLI7F7XRE0P">refused</a> to approve Capricor’s application for Deramiocel for the treatment of Duchenne muscular dystrophy, stating that it does not meet the requirement for substantial evidence of effectiveness, while also expressing the need for additional clinical data. The company said at the time that it intends to meet the FDA’s additional clinical data requirement with a late-stage study and resubmit its application.In December, the company provided the FDA with results from its late-stage HOPE-3 study in which Deramiocel delivered strong signals of benefit for muscle and heart function. However, after reviewing the data, the FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. The agency, however, did not request any additional clinical studies or new patient data, it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/335/capricor-therapeutics-provides-regulatory-update-on">added.</a><h2 class="st-heading-2">Fresh Timelines</h2>Capricor now plans to submit the new data requested by the FDA in February and expects that the submission will support continued review of its application and address the concerns raised by the FDA in July. &nbsp;CEO of Capricor, Linda Marbán, said that the company is “pleased” that the FDA requested the clinical study report, adding that the request was expected.“Our near-term priority is to address the FDA’s request and continue working collaboratively so that patients with late-stage DMD, who currently have very limited treatment options, may gain access to Deramiocel as soon as possible,” Marbán added.DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user voiced optimism for the drug getting approved in the following three to five months.<stembedurl>https://www.stocktwits.com/jamestrade07/message/642322958</stembedurl>Another user voiced hopes for the stock touching as much as $100 by end of year following Deramiocel approval.<stembedurl>https://www.stocktwits.com/haha1978/message/642314942</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 69% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?

The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 

Equity

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - Here's Why

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Above 50-Day Moving Average - Time to Sell...

Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen

Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8% - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7.8% - Here's Why...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat...

Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen

Wall Street Zen raised Capricor Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5% - Here's What Happened

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5% - Should You Sell...

HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC raised its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 33.7% in the third quarter, according to the company in its most recent disclosure with the...

HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR

HBK Sorce Advisory LLC lifted its stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 36.6% during the third quarter, according to the company in its most recent filing with...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

No change

25 bps cut

25 bps hike

Note sure, just watching

The Fed announces its rate decision this Wednesday.

Markets are pricing in a ~99% chance of no change at this week’s Fed decision, according to prediction markets. $SPY $QQQ 

FOMC on Wednesday, what do you think the Fed will decide?

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc